Appointment of Joint Broker

 

TIDMLPX 
 
RNS Number : 9277P 
Lipoxen PLC 
01 April 2009 
 

1 April 2009 
 
 
Lipoxen PLC 
('Lipoxen' or the 'Company') 
 
 
Appointment of Joint Broker 
 
 
 
 
 
 
The Board of Lipoxen announces the appointment of Noble & Company ("Noble") as 
joint broker to the Company with immediate effect. 
 
 
=- Ends -- 
 
 
 
 
 
 
Enquiries: 
 
 
+-------------------------------------------+---------+----------------------------+ 
| Lipoxen PLC                               |                                      | 
+-------------------------------------------+--------------------------------------+ 
| M. Scott Maguire                          | Tel:  [phone]           | 
| Chief Executive Officer                   |                                      | 
+-------------------------------------------+--------------------------------------+ 
|                                           |                                      | 
+-------------------------------------------+--------------------------------------+ 
| Noble & Company                                     |                            | 
+-----------------------------------------------------+----------------------------+ 
| John Llewellyn-Lloyd                                | Tel: [phone]  | 
+-----------------------------------------------------+----------------------------+ 
| Sam Reynolds                                        |                            | 
|                                                     |                            | 
+-----------------------------------------------------+----------------------------+ 
| Citigate Dewe Rogerson                              |                            | 
+-----------------------------------------------------+----------------------------+ 
| David Dible / Mark Swallow                          | Tel: [phone]  | 
+-------------------------------------------+---------+----------------------------+ 
 
 
 
 
Notes to Editors on Lipoxen: 
 
 
Lipoxen PLC (AIM:LPX) is a biopharmaceutical company specializing in the 
development of high value differentiated biologicals, vaccines and oncology 
drugs based on its proprietary delivery platforms. Lipoxen's PolyXen delivery 
technology is designed to improve the stability, biological half-life and 
immunologic characteristics of therapeutic proteins naturally Lipoxen currently 
has two products in clinical development using PolyXen, SuliXen, a long acting 
insulin and ErepoXen a long-acting erythropoietin (EPO). Phase I results with 
these novel products have shown that they have potential to deliver important 
dosing advantages to product currently on the market. Both SuliXen and ErepoXen 
are addressing multi billion dollar markets. Further products under development 
include improved formulations of important biologicals such as G-CSF, and 
Interferon-alpha. 
 
 
Lipoxen has a second naturally-derived proprietary delivery technology, 
ImuXen[R] and a related liposomal technology for enhancing the efficacy and 
safety of various vaccines including multivalent Hepatitis B-E and pneumococcal 
vaccines. The Company's proprietary delivery technologies are attracting 
significant interest and Lipoxen is currently co-developing products with the 
Serum Institute of India Limited (one of the world's leading vaccine companies, 
India's largest biotech company and a major shareholder in Lipoxen) and has 
license agreements in place with Baxter International and Schering Plough . 
Lipoxen has received funding from the International AIDS Vaccine Initiative 
(IAVI) to assess the potential of its ImuXen technology to develop an improved 
HIV vaccine. The Company is also working in collaboration on improved vaccine 
formulations that could be suitable for refrigeration free distribution, which 
would enable vaccines to be much more widely distributed to people in the 
developing world. 
 
 
Lipoxen was admitted to trading on the AIM Market of the London Stock Exchange 
in January 2006. 
 
 
www.lipoxen.com 
 
 
Notes to Editors on Noble: 
 
 
Noble is a research-led independent Anglo-Indian investment bank dedicated to 
mid- and small-cap companies. It provides a full range of services to companies, 
institutions and investment vehicles, with offices in London, Edinburgh and 
Mumbai. 
 
 
Noble publishes high quality fundamental research on more than 170 companies in 
UK and India. In investment banking, Noble acts as sponsor, takeover adviser and 
broker on AIM, sponsor and broker on the LSE main market and adviser on Plus. 
 
 
Noble has five operating companies in the UK, covering Investment Banking, 
Investment Management and Growth Capital, all of which are authorised and 
regulated by the Financial Services Authority. 
 
 
www.noblegp.com 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCUUUAUCUPBGPG